GH Receptor Antagonist: Mechanism of Action and Clinical Utility

被引：0
|
作者：
Sowmya K. Surya
Ariel L. Barkan
机构：
[1] University of Michigan Hospitals,Division of Endocrinology
来源：
Reviews in Endocrine and Metabolic Disorders | 2005年 / 6卷
关键词：
acromegaly; GH receptor antagonists; Pegvisomant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
This review focuses on the development of GH receptor antagonist as a novel agent for treatment of acromegaly, its mechanism of action and potential areas of use. A brief overview of acromegaly, its diagnosis and existing medical, surgical and radiotherapy options of treatment is necessary to justify the addition of yet another therapeutic modality to the already vast therapeutic armamentarium.
引用
收藏
页码：5 / 13
页数：8
相关论文
共 50 条
  • [1] GH receptor antagonist: Mechanism of action and clinical utility
    Surya, SK
    Barkan, AL
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2005, 6 (01): : 5 - 13
  • [2] A CLINICAL STUDY ON MECHANISM OF ANTIARRHYTHMIC ACTION OF A NEW ANTAGONIST TO BETA-ADRENERGIC RECEPTOR
    LINKO, E
    RUOSTEENOJA, R
    SIITONEN, L
    AMERICAN HEART JOURNAL, 1968, 75 (01) : 139 - +
  • [3] Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
    Osborne, CK
    Wakeling, A
    Nicholson, RI
    BRITISH JOURNAL OF CANCER, 2004, 90 (Suppl 1) : S2 - S6
  • [4] Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
    C K Osborne
    A Wakeling
    R I Nicholson
    British Journal of Cancer, 2004, 90 : S2 - S6
  • [5] Ifenprodil, a novel NMDA receptor antagonist: Site and mechanism of action
    Williams, K
    CURRENT DRUG TARGETS, 2001, 2 (03) : 285 - 298
  • [6] Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization
    Harding, PA
    Wang, XZ
    Okada, S
    Chen, WY
    Wan, W
    Kopchick, JJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (12) : 6708 - 6712
  • [7] Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indications
    Kopchick, John J.
    List, Edward O.
    Kelder, Bruce
    Gosney, Elahu S.
    Berryman, Darlene E.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2014, 386 (1-2) : 34 - 45
  • [8] ON THE MECHANISM OF THE PROLONGED ACTION IN MAN OF GR32191, A THROMBOXANE RECEPTOR ANTAGONIST
    RITTER, JM
    DOKTOR, HS
    BENJAMIN, N
    BARROW, SE
    STEWARTLONG, P
    ADVANCES IN PROSTAGLANDIN THROMBOXANE AND LEUKOTRIENE RESEARCH, 1991, 21 : 351 - 354
  • [9] Preclinical Efficacy and Mechanism of Action of a Potent Small Molecule Glucagon Receptor Antagonist
    Mu, James
    Qureshi, Sajjad
    Brady, Ed
    Candelore, Mari R.
    Muise, Eric
    Li, Zhihua
    Yang, Xiaodong
    Guo, Jian
    Xiong, Yusheng
    Parmee, Emma R.
    Zhang, Bei B.
    DIABETES, 2010, 59 : A406 - A406
  • [10] STUDIES ON THE MECHANISM OF ACTION OF WIN-49596 - A STEROIDAL ANDROGEN RECEPTOR ANTAGONIST
    WINNEKER, RC
    WAGNER, MM
    BATZOLD, FH
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1989, 33 (06): : 1133 - 1138
12345